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Abstract
We demonstrate here a rapid alternative method for the production of functional bi-specific antibodies using the mild
reducing agent 2-mercaptoethanesulfonic acid sodium salt (MESNA). Following reduction of a mixture of two monoclonal
antibodies with MESNA to break inter heavy chain bonds, this solution is dialysed under oxidising conditions and antibodies
are allowed to reform. During this reaction a mixture of antibodies is formed, including parental antibodies and bi-specific
antibody. Bi-specific antibodies are purified over two sequential affinity columns. Following purification, bi-specificity of
antibodies is determined in enzyme-linked immunosorbent assays and by flow cytometry. Using this redox method we have
been successful in producing hybrid and same-species bi-specific antibodies in a time frame of 6–10 working days, making
this production method a time saving alternative to the time-consuming traditional heterohybridoma technology for the
production of bi-specific antibodies for use in early pilot studies. The use of both rat and mouse IgG antibodies forming a
rat/mouse bi-specific antibody as well as producing a pure mouse bi-specific antibody and a pure rat bi-specific antibody
demonstrates the flexibility of this production method.
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Introduction
Ko ¨hler and Milstein [1] pioneered hybridoma technology and
thereby opened the possibility to manufacture pure monoclonal
antibody (mAb) in large amounts. MAbs are not generally efficient
on their own as immunotherapeutic agents and have therefore
been attached or conjugated to more potent agents including
toxins, radionucleotides and cytotoxic drugs. Whereas mAbs are
specific for one epitope, bi-specific antibodies (bsAb) are able to
recognize two epitopes on the same or a distinct antigen simul-
taneously. Although bsAbs have attracted attention as candidates
for cancer therapy [2], they have encountered obstacles including
improper heterodimer formation and low yields [3,4]. Tradition-
ally, bsAbs have been produced using hybrid hybridoma tech-
nology [5], which relies on time-consuming tissue culture
methodology. Additionally, co-expression of two immunoglobulin
G (IgG) molecules in a hybrid hybridoma can produce up to 10
different heavy and light-chain pairings leading to a low yield of
the required bi-specific antibody [6]. Finally, separation of bsAb
from other immunoglobulins in supernatant can be very difficult,
particularly when the two component mAbs are from the same
species and subclass. Another approach taken in order to produce
bsAbs involves chemical conjugation of two antibodies or two
antibody fragments [7]. Problems using this method include the
inactivation, unfolding or aggregation of the bsAb due to the
chemical conditions used during the production. A more recent
approach taken by several researchers involves the use of
molecular means to produce a range of bsAb including: single
chain variable fragment (scFv) fusions or diabodies, scFv Fc fusions
and single variable domain IgGs as well as dual-variable domain
IgG [8–11].
We have developed a chemical reduction-oxidation (redox)
method for the production of purified bsAbs in a fraction of the
time taken by the traditional hybrid hybridoma technology by
using the mild reducing agent 2-mercaptoethanesulfonic acid
sodium salt (MESNA) followed by dialysis under oxidising
conditions in order to allow antibodies to reform. During this
reaction a mixture of antibodies is formed, including parental
antibodies and bi-specific antibody. Bi-specific antibodies are
highly purified over two sequential affinity columns. We show here
the production of several different bsAbs that have been purified to
homogeneity using affinity columns. A simplified schematic
overview of this novel redox method can be seen in Figure 1.
To demonstrate that it is possible to make bsAbs using mAbs from
different species we have made rat/mouse hybrid bsAbs and
purified these, first over an anti-rat IgG and secondly an anti-
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that it is possible to make bsAbs using two different antibodies
from the same species and subclass. In order to purify these bsAbs
the parental antibodies were conjugated to biotin or dinitrophenol
prior to reduction using MESNA. Purification of bsAbs was
carried out by sequential purification on anti-biotin and anti-DNP
affinity columns. All bsAbs produced have the ability to
simultaneously bind two antigens and show functionality in vitro
as demonstrated by enzyme linked immunosorbent assay (ELISA)
and by flow cytometry.
Materials and Methods
Monoclonal antibodies
Antibodies used were rat anti-b-galactosidase mAb (clone
GL117, IgG2a) [12], rat anti-mouse CD40 mAbs (clone 1C10,
IgG2a and clone 10C8, IgG1) [12], mouse anti-human CD40
mAb (clone G28/5, IgG2a) [13] and mouse A20 IgG mAb (IgG2a)
[14]. A20 IgG is a tumor idiotype and is expressed on a BALB/c B
cell lymphoma originally derived from a spontaneous reticulum
cell neoplasm. The specificity of the A20 mAb is unknown.
Redox methodology
100 mM 2-mercaptoethanesulfonic acid sodium salt (MESNA;
Sigma-Aldrich, Gillingham, UK) was used to reduce mAb to
monovalent antibody (mvAb) by adding an equal volume of two
times concentrated MESNA solution in dH2O [15] to a mixture of
1 mg mAb 1 and 1 mg of mAb 2 in PBS and incubated at 37uC
for 25 minutes. Thereafter mvAbs were exposed to oxidising
conditions by dialysis against three buffer exchanges of phosphate
buffered saline (PBS), pH 7.4 over 24 h at 4uC. Bi-specific
antibody was purified from parental antibody over sequential
affinity columns to assure only pure bsAb was assayed. The eluted
fraction from column one was dialyzed against PBS and
subsequently purified over column two with the eluted fraction
from this column containing bsAb. BsAb concentration was
determined using a micro BCA protein assay kit (Thermo
Scientific, Rockford, USA).
Hybrid bsAb production and purification
For production of hybrid bsAbs 1 mg of GL117 mAb and 1 mg
of A20 mAb or 1 mg of 1C10 mAb and 1 mg of A20 mAb were
reduced with MESNA as described above. Bi-specific antibody was
purified from parental antibody over affinity column one (GE
Healthcare, St Giles, UK), coupled with affinipure goat anti-rat IgG
(minimum cross reaction with mouse, human, bovine, horse and
rabbit serum proteins; Jackson ImmunoResearch Europe Ltd,
Newmarket, UK). Antibody mixture was applied manually ‘drop to
drop’ using a syringe at a flow rate of 1 ml/min. Bound antibody
was eluted using 0.1 M Glycine-HCl, pH 2.7 and the pH of the
eluate was neutralized by the addition of a 1/10 dilution 1.0 M
Tris-HCl, pH 9.0. The eluted fraction from the anti-rat column was
dialyzed against three changes of PBS and subsequently purified
over an affinipure goat anti-mouse IgG (minimum cross reaction
with rat, human, bovine, horse and rabbit serum proteins; Jackson
ImmunoResearch), as described for the anti-rat column with the
eluted fraction from this column containing bsAb.
Screening ELISA 1 – recognition of hybrid bsAb by anti-
rat and anti-mouse heavy chain antibodies
Ten mg/ml goat anti-rat IgG (AbD SeroTec, Kidlington, UK)
in PBS was adsorbed to 96-well ELISA plates for 16 h at 4uC. In
all ELISA assays described the incubation steps were at room
temperature for 1 hour and following each incubation step plates
were washed with PBS +0.05% Tween 20, and plates blocked with
5% (v/v) bovine serum albumin (BSA; Sigma Aldrich) unless
specified otherwise. Samples were added at a two-fold dilution
from the neat sample and further two fold serial dilutions of bsAb
and parental mAbs in PBS were added to the plates. Plates were
incubated with peroxidase conjugated polyclonal anti-mouse Ig
(multiple adsorbed; BD Biosciences, Oxford, UK). Substrate (o-
phenylenediamine dihydrochloride; Sigma Aldrich) was added
and following colour development absorbance read at 450 nm
using an ELISA plate reader (ELX808, Bio-Tek Instruments Inc.,
Potton, UK).
Screening ELISA 2 - Binding of hybrid bsAb to
b-galactosidase and simultaneous recognition by
anti-mouse IgG heavy chain
Recombinant purified b-gal protein (Alpha Laboratories, East-
leigh, UK) at a concentration of 5 mg/ml in PBS was adsorbed to
Figure 1. Redox method overview. MAb 1 and mAb 2 are mixed
and reduced using MESNA, resulting in mvAb fragments being formed
as visualized by SDS-PAGE. When dialysed into oxidising conditions
mAbs are reformed resulting in a mixture of parental and bi-specific
antibodies. In order to get a pure bsAb solution, antibodies are purified
over two sequential affinity columns, each one specific for the one mAb
only. After affinity column one the eluate containing mAb 1 and bsAb is
purified on column 2. The resulting eluate contains pure bsAb that can
be used for further applications.
doi:10.1371/journal.pone.0022533.g001
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described for assay 1.
Screening ELISA 3 – Binding of hybrid bsAb mouse CD40
and simultaneous recognition by anti-mouse IgG heavy
chain
Ten mg/ml anti-human IgG (Fc specific; Sigma Aldrich) in PBS
was adsorbed to 96-well ELISA plates for 16 h at 4uC.
Recombinant mouse CD40/HuFc chimera (R&D Systems Europe
Ltd., Abingdon, UK) was added at 0.1 mg/ml in PBS for 1 h at
room temperature. The assay was finished as described for assay 1.
Determination of functionality of hybrid bsAbs using
flow cytometry
CD40L cells are stably transfected murine L929 fibroblast cells
that express murine CD40 on their cell surface [16]. These cells
were used to ensure rat anti-mouse CD40 hybridised with mouse
IgG was able to bind to native CD40 in vitro. Cells were prepared
for cell surface flow cytometric analysis and incubated with 1–5 mg
hybrid bsAb and relevant controls for 30 min on ice in PBS +0.1%
(v/v) BSA. Cells were washed twice by centrifugation at 400 x g for
5 min. To detect staining, CD40L cells were incubated with a
secondary anti-mouse IgG-FITC mAb (BD Biosciences) for
30 min on ice in PBS +0.1% (v/v) BSA. Following two
centrifugation steps in PBS +0.1% (v/v) BSA cells were analysed
on a FACSCalibur (BD Biosciences) or an LSRII (BD Biosciences).
TO-PROH-3-iodide (Invitrogen Ltd, Paisley, UK) was added
immediately prior to analysis at a final concentration of 0.3 mMt o
allow dead cell exclusion. Data analysis was carried out using
FlowJo
TM software (Tree Star Inc., Ashland, USA).
Production of same species bsAbs
In order to be able to purify bi-specific antibodies made from
the same species and antibody subclass, parent antibodies were
pre-labeled with biotin or DNP prior to redox exposure.
Antibody biotinylation
Antibody was buffer exchanged into 0.1 M NaHCO3 using
dialysis prior to biotinylation. (+)-Biotin-N-hydroxysuccinimide
ester (Sigma Aldrich) was dissolved in DMSO (Sigma Aldrich) to
give 10 mg/ml and 80 mg of biotin was added per mg of antibody
and incubated for 4 hours at room temperature in the dark during
continuous rotation on a MACSMix (Miltenyi Biotech Ltd., Bisley,
UK). Biotinylated antibody was buffer exchanged into PBS
pH 7.4, using dialysis over 24 h at 4uC and thereafter used in
further applications.
Haptenation of antibodies using DNFB
Dinitrophenol was conjugated to mouse A20 IgG mAb as
previously described [17]. Briefly, 1-fluoro-2,4-dinitrobenzene
(DNFB; Sigma Aldrich) was diluted in chloroform to 50 mg/ml.
Mouse or rat mAb at 10 mg/ml in 0.1 M NaHCO3 was combined
with DNFB at a working concentration of 0.5 mg/ml and
incubated at 37uC for 45–60 minutes in the dark during
continuous rotation on a MACSMix. The haptenised antibody
was subsequently dialysed into PBS over 24 h at 4uC and used in
further applications.
Production and purification of same species bsAb
For production of a mouse bsAb 1 mg of DNP labeled G28/5
mAb and 1 mg of biotinylated A20 mAb (both mouse IgG2a) were
mixed. Additionally, for the production of a rat bsAb 1 mg DNP
labeled 1C10 mAb and 1 mg biotinylated GL117 mAb (both rat
IgG2a) were mixed and incubated with MESNA as described
above. Following dialysis into PBS bivalent antibody was purified
from parental antibody over Amino-link plus affinity columns
(Thermo Scientific). Column one was coupled with anti-biotin
antibody (Thermo Scientific) following the manufacturers’instruc-
tions. The eluted fraction from the anti-biotin column was dialysed
against PBS and subsequently purified over a column coupled with
anti-DNP antibody (Bethyl Laboratories, Universal Biologicals
Ltd, Cambridge, UK), with the eluted fraction from this column
containing bsAb.
Figure 2. Redox method optimisation. Non-reducing SDS-PAGE
showing the range of MESNA concentrations used in optimisation
studies for GL117 mAb (a). Arrows indicate presence of whole mAb (1),
mvAb (2), heavy chain (3) and light chain (4). 50 mM MESNA efficiently
cleaves inter heavy chains in GL117 mAb resulting in a band at around
90 kDa (b) and in A20 mAb at around 95 kDa (c). Dialysis into PBS
shows successful reformation of mvAb into whole mAb (d). Image
shows in lane order; molecular weight standard, parental GL117 mAb
and parental A20 mAb (both .170 kDa), MESNA-reduced GL117 and
A20 mvAb mixture (90–110 kDa) and reformed whole antibody,
including bi-specific GL117-A20 bsAb. Molecular weight (MW) marker
PageRuler pre-stained protein ladder 10–170 kDa (Fermentas GmbH, St.
Leon-Rot, Germany). Red. = Reducing conditions, Oxid. = Oxidising
conditions.
doi:10.1371/journal.pone.0022533.g002
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PLoS ONE | www.plosone.org 3 July 2011 | Volume 6 | Issue 7 | e22533Figure 3. Verification of antigen recognition by hybrid bsAbs. The presence of GL117-A20 bsAb (a) and 1C10-A20 bsAb (b) was verified by
simultaneous recognition of anti-rat IgG and anti-mouse IgG in ELISA assay 1 as visualized by an increase in the OD reading at 450 nm compared to
parental mAbs. Antigen recognition of b-gal and recognition by an anti-mouse IgG antibody was determined in ELISA assay 2 showing the presence
of hybrid GL117-A20 bsAb after binding of the GL117 binding arm to b-gal and the A20 binding arm to anti-mouse IgG (c). CD40 specificity and
subsequent recognition by an anti-mouse IgG antibody was determined in ELISA assay 3 and this showed the presence of 1C10-A20 bsAb by the
binding of the 1C10-binding arm to CD40 and the A20 binding arm to anti-mouse IgG (d). Flow cytometric analysis on viable CD40L cells showed an
increase in median fluorescence after incubation with 1C10-A20 bsAb but not GL117-A20 bsAb (e). Neg CTL = negative control.
doi:10.1371/journal.pone.0022533.g003
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To determine that antibody labeling had been successful and
that same species bsAb had been generated two ELISA assays
were designed.
Determination of DNP and biotin presence on bsAb
Goat anti-DNP antibody was adsorbed to 96-well ELISA plates
at 2 mg/ml in PBS for 16 h at 4uC. The ELISA was performed as
described for assay 1 using streptavidin horseradish peroxidase
(Vector Laboratories Inc., Peterborough, UK) at 0.5 mg/ml for
detection.
Binding to human CD40 and detection by SA-HRP
simultaneously
Recombinant human CD40/HuFc was directly adsorbed to 96-
well ELISA plates at 5 mg/ml in 0.1 M sodium carbonate buffer
for 16 h at RT. The ELISA was performed as described for assay
1 using streptavidin horseradish peroxidase (Vector Laboratories)
at 0.5 mg/ml as the detection antibody.
Results and Discussion
We have successfully produced several bsAbs using this redox
technology, including hybrid rat/mouse and same species bsAbs.
Hybrid rat/mouse bsAbs include GL117-A20 bsAb and 1C10-
A20 bsAb and same species bsAbs include mouse G28/5-A20
bsAb and rat 1C10-GL117 bsAb. For simplicity most of the
optimisation results shown are for the GL117-A20 bsAb, however
the redox production method was identical for all bsAbs, with the
exception of the use of different affinity columns for purification
purposes of hybrid and same species bsAbs.
To optimise reduction conditions an initial time course
experiment was carried out. Following analysis of samples reduced
by MESNA by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) under non-reducing conditions it
was determined that incubation at 37uC for 25 minutes was
optimal (data not shown). To further optimise reduction conditions
for each antibody MESNA was added to a final concentration of
50, 20, 10, 5, 2, and 1 mM to the antibody of choice. Figure 2a
shows the range of MESNA concentrations used for the reduction
of A20 mAb to mvAb. The optimum MESNA concentration for
use was determined to be 50 mM for A20 mAb and GL117 mAb
and 20 mM for 1C10 mAb and G28/5 mAb, as at these
concentrations very small amounts of whole antibody is still
present. All antibodies used in this study were effectively reduced
to mvAb at their optimum MESNA concentration. As can be seen
in Figure 2a, reduction with MESNA results in the release of some
free heavy and light chain. Efficient mvAb formation yielded a
band at a molecular weight ranging from 72 to 110 kDa,
depending on antibody used. Figures 2b and 2c further illustrate
the efficient cleavage of the inter-heavy chain disulfide bonds in
GL117 and A20 antibodies after reduction with 50 mM MESNA
resulting in mvAbs of approximately 90 kDa and 110 kDa,
respectively.
The successful reformation of the inter-heavy chain disulfide
bonds of A20 mvAb and GL117 mvAb following dialysis in PBS
was visualized using non-reducing SDS-PAGE and is shown in
Figure 2d. The loss of the band at 90–110 kDa verifies
reformation of whole antibody molecules. After oxidation, the
free light chain is no longer present indicating that this is reformed
with the heavy chain to produce whole antibody molecules.
Screening of hybrid bsAb was by ELISA and flow cytometry as
described in the methods section. Screening of the hybrid rat/
mouse bi-specific antibody was initially based on the recognition of
mouse and rat antibodies simultaneously using ELISA assay 1 and
this is shown in Figure 3. As only bsAb, and not the parental
antibodies, is recognized by anti-mouse capture and anti-rat
detection antibodies simultaneously, this assay verifies the presence
of bsAb. The superior binding ability of both GL117-A20 bsAb
and 1C10-A20 bsAb compared to their parental counterparts is
shown in Figure 3a and 3b respectively.
The in vitro functionality (antigen binding) of GL117-A20 bsAb
was verified in ELISA assay 2 in which recombinant b-gal was
bound to the plate. Figure 3c shows binding of the bsAb only, and
not of parental antibodies, to b-gal and recognition by anti-mouse
antibody simultaneously, providing further evidence that func-
tional bsAb was produced.
To check functionality of the second hybrid rat/mouse bsAb
1C10-A20 its binding to mouse CD40 via the rat IgG component
was verified by ELISA using assay 3 and by flow cytometry on
CD40L cells. Figure 3d shows binding of 1C10-A20 bsAb to
mouse CD40 and the simultaneous detection by an anti-mouse
IgG antibody in the ELISA. Despite some non-specific back-
ground binding in this assay, we showed that the recognition by
1C10-A20 bsAb of mouse CD40 was specific as determined by
flow cytometry using CD40 expressing L929 fibroblast cells. The
addition of TO-PROH-3-iodide prior to analysis allowed the
Figure 4. Verification of antigen recognition by same species
bsAbs. Same species bsAb was detected using a sandwich ELISA
specific for biotin or DNP. Pre-labeling of G28/5 and 1C10 with DNP and
A20 and GL117 with biotin allowed binding of 1C10-GL117 bsAb and
G28/5-A20 bsAb and not parental antibodies in this assay (a and b
respectively).
doi:10.1371/journal.pone.0022533.g004
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The flow cytometry overlay plot in Figure 3e shows that GL117-
A20 bsAb, which is specific for b-gal, does not bind to live CD40L
cells; however, the 1C10-A20 bsAb including the anti-CD40
binding arm is able to bind to these cells.
In addition to the production of hybrid rat/mouse bsAbs, same
species mouse and rat bsAbs were made. In order to be able to
purify bi-specific antibodies made from the same species, the
component antibodies were pre-labeled with biotin or DNP.
Following redox the labeled bsAbs were purified over an anti-
biotin column followed by an anti-DNP column. To ensure bsAbs
were produced these were screened using an anti-biotin and anti-
DNP ELISA. Only bsAb carrying the dual labels will be positive in
this assay. Figure 4a shows the successful generation of the rat
1C10-GL117 bsAb and Figure 4b a G28/5-A20 mouse bsAb. This
data illustrates that it is possible to make bsAb after pre-
conjugation to biotin and DNP.
We have shown here that this redox method can be used to
produce antigen binding bi-specific antibodies both from different
species and most importantly using mAbs of the same subclass and
same species. In order to purify these same species bsAbs we
labeled the starting material with biotin or DNP. Biotin is one of
the eight essential vitamins that comprise the B complex; it is non-
toxic and is not known to have any side effects in humans [18].
DNP, being a phenolic compound with potential carcinogenicity
would not be ideal for clinical use, but there is a vast array of
potential safe haptens available for this purpose. We have simply
used DNP as a label in this study to prove in principle that this
method works. Production and purification of bsAbs from same
species and same subclass starting material using the redox method
has in this study been achieved within 3–4 days, Determination of
the bsAb specificity and functionality by ELISA and flow
cytometry was carried out over the subsequent 3–6 days making
the total time frame of production 6–9 days. To produce a bsAb
using conventional heterohybridoma methods within the same
time frame could be extremely difficult and therefore the use of the
redox method will be useful in early pilot studies.
Nineteen percent of the antibody recovered following purifica-
tion on affinity columns (eluate and flow through) bound to both
the columns and was therefore bi-specific. Parental mAb that does
not bind to the affinity column can be re-used and exposed to the
redox method again potentially increasing the bsAb yield.
Although the yield from the redox method is not higher than
from the use of traditional methods, it may be sufficient to provide
enough material for single patient use. Bargou et al. have
demonstrated that low amounts of bsAb may be sufficient for
successful cancer therapy. The bi-specific T cell engager (BiTE),
blinatumomab, which has dual specificity for CD19 and CD3, was
used to treat non-Hodgkin’ B cell lymphoma. Results from this
clinical trial showed tumor reduction after four weeks of daily
bsAb immunisations of doses from 0.0005 to 0.6 mg/m
2. The
most effective dose was found to be 0.015 mg/m
2, indicating that
for a potent antibody very small amounts of bsAb may be effective
for cancer immunotherapy [19].
In conclusion, we have produced several different bsAb
molecules of different specificities using the redox technology.
This methodology is widely applicable as it can be used for any
two mAbs potentially producing any bsAb of choice and has
proved for us to be a successful rapid alternative to the traditional
heterohybridoma technology for the production of bi-specific
antibodies thereby providing a timesaving solution for early pilot
studies.
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